Lack of awareness about rare diseases, such as hereditary angioedema (HAE), contributes to their often long and delayed diagnosis, a study suggests. The study, “Why does it take so long for rare disease patients to get an accurate diagnosis?—A qualitative investigation of patient experiences of hereditary angioedema,” was…
News
Intellia Therapeutics has completed dosing the first group of patients enrolled in a Phase 1/2 clinical trial testing its gene-editing therapy, NTLA-2002, for the treatment of hereditary angioedema (HAE). In the Phase 1 part of the study (NCT05120830), patients will receive a single infusion of NTLA-2002, delivered into…
HAE Awareness Day is observed around the world each May 16 to bring attention to hereditary angioedema (HAE) and those people the disorder affects. The goal is to heighten awareness among the general public, as well as healthcare professionals, decision-makers, and industry representatives. The theme for this year’s observance…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Takeda Canada has won a bid making it Héma-Québec’s sole source of Takhzyro (lanadelumab) — an approved under-the-skin treatment to prevent attacks of hereditary angioedema (HAE) — through at least 2024. Takhzyro is now available as a prophylaxis treatment for people with HAE in Québec, according to…
A common over-the-counter painkiller induced two allergic reactions — one of them leading to angioedema, and another to skin lesions — in a case study of a 41-year-old man. The report, “Angioedema and fixed drug eruption simultaneously induced by naproxen sodium: A rare clinical entity,” was…
In rare cases, stroke-like symptoms, such as tingling in the face and the left arm, can occur during an acute attack of hereditary angioedema (HAE), a case study reports. The patient, a woman in her 30s, developed facial swelling and abdominal pain. All her symptoms resolved with treatment with…
A fully assembled, prefilled syringe form of Takeda’s Takhzyro (lanadelumab), approved to prevent swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE), is now available in the U.S. “HAE attacks are unpredictable, debilitating and in some cases life-threatening, adding uncertainty and complexity to the…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…
A man who had been treated with the blood pressure medication losartan for 20 years experienced sudden angioedema after upping the medication’s dose, according to a recent case report. “This is the first documented case of angioedema presenting in a dose-dependent manner with losartan use. We hope that our…
Recent Posts
- A roller coaster of a year gave me new insights about living with HAE
- 1-year trial data: Orladeyo cuts swelling attacks in young children
- 1 lonvo-z dose keeps most HAE patients attack-free up to 3 years
- For many of us, becoming a patient advocate wasn’t optional
- FDA extends Orladeyo approval to children as young as 2